A Phase I Randomized, Observer-Blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of Two Intramuscular Doses of DPX-RSV(A), a Respiratory Syncytial Virus (RSV) Vaccine Containing RSV SH Antigen and a Novel Adjuvant DepoVax, or SH Antigen Co-administered With Aluminum Hydroxide, or Placebo to Healthy Adults ≥50–64 Years of Age | Zendy

Joanne M. Langley | Zendy; Lisa D. MacDonald | Zendy; Genevieve Weir | Zendy; Donna MacKinCameron | Zendy; Lingyun Ye | Zendy; Shelly McNeil | Zendy; Bert Schepens | Zendy; Xavier Saelens | Zendy; Marianne M. Stanford | Zendy; Scott A. Halperin | Zendy

Open Access

A Phase I Randomized, Observer-Blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of Two Intramuscular Doses of DPX-RSV(A), a Respiratory Syncytial Virus (RSV) Vaccine Containing RSV SH Antigen and a Novel Adjuvant DepoVax, or SH Antigen Co-administered With Aluminum Hydroxide, or Placebo to Healthy Adults ≥50–64 Years of Age

Author(s) -

Joanne M. Langley,

Lisa D. MacDonald,

Genevieve Weir,

Donna MacKinCameron,

Lingyun Ye,

Shelly McNeil,

Bert Schepens,

Xavier Saelens,

Marianne M. Stanford,

Scott A. Halperin

Publication year - 2016